A growing body of literature suggests Breast Cancer-Associated Protein 1 (BRCA1) is important not only as a cause, but also as a target in the quest for cancer treatment. BRCA1 deficient cells treated with radiation as well as PARP inhibitors and other chemotherapeutics demonstrate a greater sensitivity than cells with wild type BRCA1. Inhibitors of BRCA1 would take advantage of this synthetic lethality and represent a significant advance in cancer treatment as well as an understanding of the biology of DNA repair. Despite significant study of BRCA1 protein and function, it is a large protein (220 KDa) that is still largely uncharacterized, but its N- and C-terminal domains have been described by significant structural data. The BRCT (BRCA1 C-Terminal) Domain is a phosphoprotein binding domain that is commonly mutated or lost in cancers and has a binding cleft seemingly very suitable for drug design. Small molecule screens have been conducted against this domain, but the resulting hits with moderate affinity have not been shown to induce BRCA1 deficient phenotypes. Phosphopeptides have also been studied as potential BRCA1 inhibitors, yet despite some having affinities in the mid-nanomolar range the presence of a phosphate is not without its pharmacologic challenges. We generated an mRNA display library with 1.3 x 10^13 cyclized peptides covalently attached to the mRNA that encoded them. Eight rounds of selection exposing the library to a GST-BRCT fusion resulted in selection of non-phosphorylated peptides that bind to a BRCT domain of BRCA1. The sequences resulting from the selection have common homologies and initial characterization has shown that these peptides may be the first viable non-phosphoserine containing inhibitors of BRCA1.

Peptides are a promising class of therapeutic candidates due to their high specificity and affinity for cellular protein targets. However, peptides are susceptible to protease degradation and are typically not cell-permeable. In efforts to design more effective peptide drug discovery systems, investigators have discovered that incorporation of non-canonical amino acids (ncAAs) and macrocyclization overcome these limitations, making peptides more drug-like. In this work, we exploit the promiscuity of wild-type aminoacyl-tRNA synthetases (aaRSs) to ‘mischarge’ ncAAs onto tRNA and ribosomally incorporate them into peptides using a cell-free translation system. We have demonstrated the ability to incorporate five ncAAs into a single peptide with near-wild type yield and fidelity. We also demonstrated the in situ incorporation of ncAAs containing azide and alkyne functionalities, enabling the use of CuAAC (click chemistry) to generate triazole-bridged cyclic peptides. When combined with bisalkylation of peptides containing two cysteines via an α,α’-dibromo-m-xylene linker, we created bicyclic peptides which are structurally similar to the highly bioactive knotted peptide natural products. Biological display methods, such as mRNA display, are powerful peptide discovery tools based on their ability to generate libraries of >1014 unique peptides. We combined our ability to incorporate ncAAs with our bicyclization technique adapted for use with mRNA display to create knotted peptide library scaffolds. We performed side-by-side monocyclic and bicyclic in vitro selections against a model protein (streptavidin). Both selections resulted in peptides with mid-nM affinity, and the bicyclic selection yielded a peptide with remarkable protease resistance. We used a new library that enables the generation of a diverse collection of linear, monocyclic and bicyclic scaffolds in one pot, increasing the likelihood of target-ligand conformational alignment. We performed a second selection against streptavidin and revealed a nearly unanimous preference for linear peptides containing an HPQ motif, a known streptavidin-binding sequence. However, when we used these libraries for in vitro selection against a biological target, DNA repair protein XRCC4, we did not observe convergence. In summary, we have developed a novel technique for production of bicyclic peptide libraries. These highly-constrained protease-stable scaffolds can be used as platforms to identify high affinity, drug-like ligands using mRNA display.

Alternative splicing is an important cellular mechanism. It allows to produce multiple protein isoforms from a limited number of genes. Regulation of alternative splicing involves cis-acting elements on pre-mRNA and trans-acting splicing factors (SR and hnRNP proteins). Because splicing occurs co-transcriptionaly, chromatin structure appears to have a role in the regulation of alternative splicing. We have studied the effect of histone acetylation on alternative splicing. We have prepared splicing reporter for alternative EDB exon, which is part of the fibronectin gene. We have shown, that the inhibition of histone deacetylases affects splicing pattern of EDB exon from the reporter in the same way as the splicing of the endogenous EDB exon. Furthermore, we have shown, that the structure of the promoter affects splicing of alternative EDB exon from splicing reporter. Currently we have found out, that the structure of the promoter influences the degree of histone H4 acetylation. Inclusion of alternative EDB exon in mRNA was inversely proportional to histon acetylation on the reporter. This work might explain why various promoters have different splicing patterns of alternative exons.

Le NMD (nonsense-mediated mRNA decay) est un mécanisme qui reconnaît et dégrade les ARNm portant un codon stop prématuré afin d’empêcher la synthèse de protéines tronquées qui pourraient avoir des effets néfastes pour la cellule ou tout simplement être non fonctionnelles. Cependant, dans un certain nombre de cas, selon la position du codon stop prématuré, la protéine tronquée qui serait synthétisée si le NMD n’existait pas, pourrait remplir complètement ou partiellement la fonction de la protéine sauvage. Il faut noter qu’un codon stop prématuré est retrouvé dans le gène responsable d’une pathologie dans un tiers des maladies génétiques et de nombreuses formes de cancer. Dans la plus grande majorité des cas, la maladie se développe non pas parce qu’une protéine tronquée non fonctionnelle ou instable est synthétisée, mais plutôt parce que le gène muté n’est pas exprimé du fait de l’intervention du NMD sur l’ARNm qui en dérive. Une nouvelle approche thérapeutique de ces maladies serait d’inhiber le NMD afin de permettre la synthèse de protéines tronquées fonctionnelles et sauver le phénotype clinique. Nous avons donc décidé de rechercher des inhibiteurs du mécanisme du NMD parmi des petites molécules chimiques. Pour cela, nous avons mis au point un système de criblage en culture cellulaire reliant l’efficacité du NMD dans une cellule avec une activité luciférase mesurable directement sur les cultures cellulaires, au moyen d’un luminomètre. A partir d’un premier criblage d’environ 1500 composés chimiques, nous avons identifié une nouvelle molécule capable d’inhiber efficacement le NMD. De façon intéressante, cette nouvelle molécule est capable également d’induire la synthèse de protéines entières à partir d’un ARNm portant un codon stop prématuré. Nous avons utilisé cet inhibiteur dans des expériences pour déterminer son potentiel thérapeutique sur des modèles cellulaires de maladies génétiques tels que la dystrophie musculaire de Duchenne, la mucoviscidose et le cancer. Nos résultats démontrent que l’inhibition du NMD peut être en effet envisagée comme une nouvelle approche thérapeutique pour des maladies causées par l’apparition d’une mutation non sens. Nous avons aussi identifié une autre molécule chimique capable d’inhiber le NMD et permettant de faire un lien entre efficacité du NMD et intégrité du cytosquelette. / MRNAs harboring a premature termination codon are rapidly degraded by a mechanism called nonsense-mediated mRNA decay (NMD). NMD is a surveillance pathway that prevents the synthesis of truncated proteins that could be harmful for the cell or simply be non-functional. However in some cases, depending on the position of the premature stop codon, the truncated protein that would be synthesized if there were no NMD would be partially or fully as functional as the wild-type protein. It is noteworthy that premature termination codons are found in approximately one-third of inherited genetic disorders and several forms of cancer. In most of cases the disease arises not because a non-functional or unstable truncated protein is synthesized, but instead because the degradation of the transcript by NMD leads to complete loss of protein production. Therefore, NMD inhibition could be an interesting therapeutic approach in some cases of nonsense-related genetic diseases in which functional truncated proteins can restore the clinical phenotype. We decided to search for NMD inhibitors among thousands of small molecules. We developed a cell-based screening method which couples NMD efficiency into the cell to a luciferase activity that can be measured directly into cells by a luminometer. From a screening of approximately 1500 compounds, we have identified one molecule capable of efficiently inhibit NMD. Interestingly, this compound is also able to induce the synthesis of full-length proteins from an mRNA bearing a premature termination codon. We evaluated the therapeutic potential of this compound in different cellular models of genetic disorders such as Duchenne’s muscular dystrophy, cystic fibrosis and cancer. Our results demonstrate that NMD inhibition in general can be considered as an useful therapeutic approach to rescue PTC consequences in genetic diseases provoked by the apparition of a nonsense mutation. We have also identified another compound that inhibits NMD and uncovers a relationship between the NMD efficiency and the integrity of the cytoskeleton.

Mon travail de thèse s’est focalisé sur l’étude fonctionnelle de deux méthyltransférases (MTases) de la structure coiffe des ARNs, les protéines nsp14 et nsp16, chez le coronavirus responsable du syndrome respiratoire du Moyen-Orient (MERS-CoV). Notre étude a démonté un processus de méthylation séquentiel. La coiffe est d’abord méthylée en position N7 par nsp14 formant la coiffe-0 (7mGpppN). La coiffe-0 est ensuite méthylée en position 2’OH du premier nucléotide de l’ARN par nsp16 stimulée par nsp10 formant une coiffe 1 (7mGpppN2’Om). De plus, nos résultats suggèrent un mécanisme de régulation allostérique de l’activité de nsp16 par nsp10. Nos résultats indiquent que l’interaction nsp10/nsp16 est régulée par la variation de concentration du SAM et/ou de SAH. Le SAM présent à une concentration physiologique, environ 100 µM dans les cellules, favorise l’assemblage du complexe nsp10/nsp16. La faible concentration intracellulaire du SAH produit accélère la dissociation du complexe nsp10/nsp16 permettant le « turnover » de la réaction enzymatique. Par ailleurs, nous avons cartographié les résidus essentiels au recrutement de l’ARN par nsp16. Les méthylations étudiées jouent un rôle important dans la réplication virale. Nous avons donc criblé des inhibiteurs des deux MTases nsp14 et nsp10/nsp16 respectivement à partir des chimiothèques « Prestwick » et « 2P2I3D ». En résumé, mon travail de thèse a décortiqué les bases moléculaires de méthylation de la coiffe chez le MERS-CoV et a permis d’identifier des inhibiteurs de MTases représentant un point de départ crucial pour le développement d’antiviraux contre les CoV. / My PhD work focused on the functional study of two cap RNA methyltransferases (MTases), nsp14 and nsp16, of the Middle-East respiratory syndrome coronavirus (MERS-CoV). Our study demonstrates a sequential methylation process. The cap is first methylated at the N7 position by nsp14 forming a cap-0 (7mGpppN). It is next methylated at the 2’OH position of the first transcribed nucleotide by nsp16 stimulated by nsp10 forming a cap-1 (7mGpppN2’Om). Furthermore, our results suggest an allosteric regulation mechanism of the nsp16 activity by nsp10. Moreover, our results indicate that the nsp10/nsp16 interaction is regulated by the variation of SAM and/or SAH concentration. SAM present at physiologic concentration, around 100µM in cells, enhances the assembly of nsp10/nsp16. The weak intracellular concentration of SAH by-product speeds up the dissociation of nsp10/nsp16 allowing the enzymatic reaction turnover. In addition, we have mapped the essential residues for the recruitment of the RNA by nsp16. The methylations studied in this work play an important role for viral replication. We have therefore screened inhibitors of nsp14 and nsp10/nsp16 MTases respectively from chemical libraries « Prestwick » and « 2P2I3D ». In summary, my PhD work deciphers the molecular bases of cap RNA methylation of MERS-CoV and identifies MTase inhibitors that represent a crucial starting point for the development of antivirals against CoV.

Hepatitis B virus (HBV) represents one of the hot topics of current basic and pharmaceutical research. Although an effective vaccine against HBV exists since 1982, the world prevalence of chronic infection is still alarming. The infection can lead to significant liver damage, often resulting in hepatocellular carcinoma. Chronic HBV infection cannot be cured due to the fact that the viral genome persists in the infected hepatocyte hidden from the host immune response as well as from the antiviral treatment. One of the novel approaches aiming for HBV cure suggests that this cccDNA pool could be destroyed using gene editing tools such as CRISPR/Cas9 system. In order to shift this gene editing system to possible medicinal application, CRISPR/Cas9 has to be specifically delivered into the target cell in order to minimize its putative off-target activity. This thesis focuses at first on the design and efficacy testing of new sgRNAs targeting HBV cccDNA and secondly, it describes modular lipid nanoparticles developed specially for delivery of the CRISPR/Cas9 system in the form of RNA. Keywords: hepatitis B virus, CRISPR/Cas9, gene editing, lipid nanoparticles, mRNA delivery, targeted delivery

No description available.

Der erste Teil der Arbeit beschreibt die Etablierung einer modifizierten Form des klassichen SILAC-Verfahrens, das in der quantitativen Massenspektrometrie zur Bestimmung von relativen Änderungen in Proteinmengen benutzt wird. Im sog. „pulsed SILAC (pSILAC)“ Verfahren werden Zellen im Zuge einer differentiellen Behandlung in Kulturmedien transferiert, die unterschiedlich Isotop-markierte Aminosäuren enthalten. Da hier die Quantifizierung auf dem Verhältnis der neusynthetisierten Proteinmengen beruht, können gezielt Unterschiede in der Proteinproduktion bestimmt werden. Mit Hilfe von pSILAC konnte im zweiten Teil der Arbeit erstmals quantitativ erfasst werden, welchen Einfluss microRNAs auf die Proteinsynthese ausüben. So konnte gezeigt werden, dass sowohl die Überexpression als auch die Repression einzelner microRNAs die Produktion hunderter Proteine beeinflussen kann. Außerdem konnten Genprodukte identifiziert werden, die ausschließlich translational reguliert werden. Die Messung von Proteinneusynthese ermöglichte auch die Bestimmung von Proteinumsatzraten, dargestellt im dritten Teil der Arbeit. Zusammen mit mRNA-Umsatzraten sowie Protein- und mRNA-Mengen bilden sie die Grundlage für eine dynamische Beschreibung zelluärer Genexpression. Durch den gleichzeitigen Einsatz des Nukleosidanalogons 4-Thiouridin (4sU) und von schweren Aminosäuren (SILAC) konnte eine metabolische Markierung neusynthetiserter mRNAs und Proteine in murinen Fibroblasten erreicht und damit eine Berechnung von Protein- und mRNA-Halbwertszeiten und absoluten Mengen für ca. 5,000 Gene ermöglicht werden. Während mRNA- und Proteinenmengen deutlich korrelierten, war zwischen mRNA- und Proteinhalbwertszeiten nur eine äußerste schwache Korrelation zu erkennen. Dennoch stehen mRNA- und Proteinumsatzraten nicht einem willkürlichen Zusammhang zu einander, da bestimmte Kombinationen von mRNA- und Proteinhalbwertszeiten eine Optimierung von Genen hinsichtlich ihrer biologischen Funktionen erkennen ließen. / The first part of the thesis describes the establishment of a modified version of the classic SILAC approach routinely used in quantitative mass spectrometry (MS) to assay relative changes in protein levels. In the newly-devised approach termed pulsed SILAC (pSILAC) differentially treated cells are transferred to culture medium supplemented with different versions of stable-isotope labeled heavy amino acids. As MS-based relative quantification is exclusively based on the newly-synthesized heavy protein amounts the method enables the detection of differences in protein production resulting from the treatment. The second part of the thesis shows the use of pSILAC to globally quantify the impact of microRNAs onto the proteome. Ectopic over-expression or knock-down of a single microRNA both affected protein production of hundreds of proteins. pSILAC identified several target genes as exclusively translationally regulated as changes in corresponding transcript levels were virtually absent. Measuring newly-synthesized protein amounts with heavy amino acids in a pulsed-labeling fashion has also been used to determine turnover rates of individual proteins, described in the third part of the present work. Along with transcript turnover as well as mRNA and protein levels they are essential for a dynamic description of gene expression. Simultaneous application of the nucleoside analogue 4-thiouridine (4sU) and heavy amino acids (SILAC) to metabolically label newly-produced mRNAs and proteins in mouse fibroblasts resulted in the calculation of mRNA and protein lifetimes and absolute levels for approximately 5,000 genes. While mRNA and protein levels were overall well correlated, a correlation between mRNA and protein half-lives was virtually absent. Yet this seemingly chaotic distribution of mRNA and protein half-lives was highly instructive since specific gene subsets have obviously evolved distinct combinations of half-lives that relate to their biological functions.

No description available.

Myotonic dystrophy (DM) is an inherited disease characterized by myotonia, insulin resistance, cardiomyopathy, and cognitive deficiencies. DM is a triplet repeat disorder, meaning that affected individuals carry anywhere between 50 and thousands of CTG/CCTG repeats in their genetic makeup. When transcribed into RNA, these repeats become “toxic” in the sense that they serve to bind and sequester important RNA binding proteins. One such family of proteins, the Muscleblind-like (MBNL) family, is important in the regulation of alternative mRNA splicing, and thus the sequestration of MBNL proteins leads to a number of mis-splicing events. Many of these events are directly correlated to DM symptoms. While there is no known cure for DM, the use of small molecules to treat symptoms is a well-characterized therapeutic tactic with immense promise. Pentamidine is a small molecule that was found to reverse mis-splicing in both DM cell and mouse models. Mechanistically, this molecule is particularly unique because unlike many small molecules, which physically displace MBNL from the toxic CUG RNA, pentamidine reduces CUG RNA levels, possibly through inhibition of CTG transcription. Chapter I summarizes alternative splicing mechanisms and regulation, defines MBNL protein structure and function, describes DM pathophysiology and molecular mechanism, and finally provides an overview of pentamidine characterization as a small molecule therapeutic. Chapter II reports the development of an in vitro T7 transcription assay, which allowed us to compare the relative efficacy by which pentamidine is able to inhibit the transcription of various repeat and non-repeat DNA sequences. This chapter further reports the characterization of a series of methylene linker analogues of pentamidine, which were also characterized through the T7 transcription assay. Chapter III details our thorough structure-activity relationship investigation of bisbenzamidine analogues of pentamidine, both in in vivo and in vitro models. Chapter IV describes our characterization of actinomycin D, a known transcription inhibitor and chemotherapeutic, within the DM disease framework. Chapter V summarizes these data, which ultimately serve as a proof of concept for the potential of CTG transcription inhibition in therapeutic contexts and broadly describe their application in other repeat diseases. This dissertation contains previously published and unpublished co-authored material. / 10000-01-01